Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
Details for the oral presentation are as follows:
|Title:||The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm|
A copy of Dr. Harris’ presentation will be accessible on the Events section of the Altimmune website.
Details for the panel discussion are as follows:
|Title:||Clinical Endpoints for NASH Trials|
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Investor & Media Contacts:
Chief Financial Officer
Source: Altimmune, Inc